Broadcast Live   |   Upload & Publish  | About  | Register  | Sign in
E-mail:
Password:
Remember me on this computer
You need to install or upgrade your Flash Player!

3B NEXUS video platform & portal supports the latest version of Macromedia Flash player.


3B PLAYER by 3B NEXUS

Close [ X ]
Copy this code to embed & stream this video on your website
 
Copy this URL to share or create a link back to this video
Prof. Dr. Burghardt Wittig
Chairman, Scientific & Strategy Board
Germany
MOLOGEN AG - Active immune therapies against cancer MGN1703 and MGN1601.
MOLOGEN’S lead products are MGN1703 and MGN1601. MGN1703 is a DNA-based cancer immuno-therapy with an outstanding safety profile. The drug is currently being investigated in a clinical trial phase II/III for the treatment of metastatic colorectal cancer. MGN1601 is a cancer vaccine against renal cell caner. In a clinical phase I/II trial the drug demonstrated a very good tolerability and showed first efficacy.

[ close ] 
Please select the appropriate option to comply with legal regulations

Individual Investor Professional Investor or Financial Advisor
This multimedia channel includes videos, webcasts and live broadcasts suitable for members of the general public over 18 years of age and not engaged in providing investment advice. Access this channel for personal interest & information only. This multimedia channel includes investor videos and webcast presentations, live broadcasts and documents intended only for authorised and regulated professionals and financial advisers eligible to provide investment advice to private investors.
I comply with these terms I comply with these terms
Remember my choice for all channels on this portal Enter Media Channel »
No reliance should be placed on the information on this site which may change without notice.
You should read the Terms & Conditions section before browsing this site.

Search in Sort By
1 2 3 4 of 4   MORE   SHOW
  Select a title or search in slides to skip chapters
00:00
, MOLOGEN AG
00:28
Cancer immunotherapies, Cancer immunotherapies: from not even mentioned in 2000 to an emerging hallmark in 2011
01:56
MIDGE, dSLIM, DNA-based, immunomodulator, Proprietary technologies: MIDGE and dSLIM
02:19
Plasmid, litigation, digestion, purification, Proprietary technologies: MIDGE production
03:26
minimalistic linear expression vectors, anti-vector immunity, necleotides, MIDGE: minimalistic linear expression vectors
06:05
Ligase, Synthetic DNA, Exonuclease, Proprietary technologies: dSLIM production
06:18
stem-loop immunomodulator, single-stranded DNA loop, nucleotides, Molecular Pattern, , dSLIM: double stem-loop immunomodulator
08:15
adjuvant and palliative tumor therapy, Radiation / Chemotherapy, GM-CSF, allogeneic tumor cells, tumor associated antigens, monotherapy, Subcutaneous injection of MGN1703, Intradermal injection of MGN1601, MIDGE and dSLIM: adjuvant and palliative tumor therapy
11:52
Product, Research, Pre-Clinic, Phase I ,Phase II, Phase III, Approval, ONCOLOGY, MGN1703-CRC, MGN1703-NSCLC, MGN1601-RCC, INFECTIOUS DISEASES, Advanced product pipeline: MGN1703 in colorectal cancer, MGN1603 in renal cancer
14:06
Therapeutic vaccination against cancer, MGN1601, mechanism of action, allogeneic tumor cells, MIDGE in MGN1601, dSLIM of MGN1601, Therapeutic vaccination against cancer: proposed mechanism of action of MGN1601
16:15
MGN1601 MGN1601, renal cancer, phase Ib/IIa, Intra-dermal injection, Endpoints, Safety, Pharmacodynamics, , MGN1601 in renal cancer (RCC): ASET trial design
17:38
Therapeutic immunomodulation MGN1703 against cancer, MGN1703, chemotherapy, Therapeutic immunomodulation against cancer
18:15
MGN1703 MGN1703, colorectal carcinoma, phase II/III trial, Metastatic colorectal, Endpoints, Placebo, MGN1703 in colorectal carcinoma (CRC): IMPACT trial design
19:33
DNA-medicine, platform technologies, DNA- and cell-based cancer therapies, product pipeline, Stock Exchange:, MOLOGEN AG - Summary
20:22
, Contact